| US 7,462,599 B2 | ||
| Use of effectors of glutaminyl and glutamate cyclases | ||
| Stephan Schilling, Halle/Saale (Germany); Torsten Hoffmann, Halle/Saale (Germany); André Johannes Niestroj, Sennewitz (Germany); Hans-Ulrich Demuth, Halle/Saale (Germany); and Ulrich Heiser, Halle/Saale (Germany) | ||
| Assigned to Probiodrug AG, Halle/Saale (Germany) | ||
| Filed on Oct. 15, 2004, as Appl. No. 10/966,645. | ||
| Claims priority of provisional application 60/512038, filed on Oct. 15, 2003. | ||
| Prior Publication US 2006/0189523 A1, Aug. 24, 2006 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C07K 5/06 (2006.01) | ||
| U.S. Cl. 514—19 [562/556; 562/557] | 14 Claims |
| 1. A method of inhibiting the conversion of N-terminal glutamic acid or glutamine residues to pyroglutamic acid residues of
at least one substrate of glutaminyl cyclase in a mammalian subject comprising:
administering to a mammalian subject in need thereof an inhibitor of glutaminyl cyclase (QC), or a pharmaceutically acceptable
salt thereof;
wherein the inhibitor of glutaminyl cyclase inhibits the conversion of N-terminal glutamic acid or glutamine residues to pyroglutamic
acid residues of at least one substrate of glutaminyl cyclase selected from the group consisting of Glu1-ADan, Glu1-ABri, [Gln3]Aβ(3-11)a, Aβ3-40/42, Aβ11-40/42, [Gln3]Aβ3-40/42, [Gln1]CCL 2, [Gln1]CCL 7, [Gln1]CCL 8, [Gln1]CCL 16, [Gln1]CCL 18, and [Gln1]Fractalkine in the mammalian subject; and
the mammalian subject is diagnosed with Familial British Dementia or Familial Danish Dementia.
|